CN108948043B - 制备用于治疗癌症的化合物的新型方法 - Google Patents

制备用于治疗癌症的化合物的新型方法 Download PDF

Info

Publication number
CN108948043B
CN108948043B CN201810758236.XA CN201810758236A CN108948043B CN 108948043 B CN108948043 B CN 108948043B CN 201810758236 A CN201810758236 A CN 201810758236A CN 108948043 B CN108948043 B CN 108948043B
Authority
CN
China
Prior art keywords
compound
formula
group
reacting
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810758236.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108948043A (zh
Inventor
S·纳加纳坦
N·古兹
M·法伊弗
C·G·索厄尔
T·博斯蒂克
J·杨
A·斯里瓦斯塔瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Exelixis Inc
Original Assignee
Genentech Inc
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Exelixis Inc filed Critical Genentech Inc
Publication of CN108948043A publication Critical patent/CN108948043A/zh
Application granted granted Critical
Publication of CN108948043B publication Critical patent/CN108948043B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201810758236.XA 2012-10-12 2013-10-14 制备用于治疗癌症的化合物的新型方法 Active CN108948043B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
US61/713,104 2012-10-12
CN201380064338.7A CN104837826B (zh) 2012-10-12 2013-10-14 制备用于治疗癌症的化合物的新型方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380064338.7A Division CN104837826B (zh) 2012-10-12 2013-10-14 制备用于治疗癌症的化合物的新型方法

Publications (2)

Publication Number Publication Date
CN108948043A CN108948043A (zh) 2018-12-07
CN108948043B true CN108948043B (zh) 2021-05-04

Family

ID=49474740

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380064338.7A Active CN104837826B (zh) 2012-10-12 2013-10-14 制备用于治疗癌症的化合物的新型方法
CN201810758236.XA Active CN108948043B (zh) 2012-10-12 2013-10-14 制备用于治疗癌症的化合物的新型方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201380064338.7A Active CN104837826B (zh) 2012-10-12 2013-10-14 制备用于治疗癌症的化合物的新型方法

Country Status (31)

Country Link
US (4) US9771347B2 (2)
EP (1) EP2909188B1 (2)
JP (2) JP6300042B2 (2)
KR (1) KR102204520B1 (2)
CN (2) CN104837826B (2)
AU (1) AU2013328929B2 (2)
BR (1) BR112015008113B1 (2)
CA (1) CA2889466C (2)
CL (1) CL2015000926A1 (2)
CR (2) CR20200237A (2)
EA (1) EA030613B1 (2)
ES (1) ES2671502T3 (2)
GE (1) GEP201706690B (2)
HK (1) HK1213567A1 (2)
HR (1) HRP20180670T1 (2)
IL (1) IL238116B (2)
IN (1) IN2015DN03928A (2)
MA (1) MA38085B1 (2)
MX (2) MX372708B (2)
MY (1) MY186549A (2)
NZ (1) NZ706723A (2)
PE (3) PE20191818A1 (2)
PH (1) PH12015500785B1 (2)
PL (1) PL2909188T3 (2)
SA (1) SA515360271B1 (2)
SG (1) SG11201502795VA (2)
SI (1) SI2909188T1 (2)
TR (1) TR201807861T4 (2)
UA (1) UA115455C2 (2)
WO (1) WO2014059422A1 (2)
ZA (1) ZA201502349B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
SI3881833T1 (sl) 2015-06-30 2024-03-29 Genentech, Inc., Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
AU2017311585A1 (en) 2016-08-12 2019-02-28 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
AU2017335839A1 (en) 2016-09-29 2019-04-18 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
CN117940130A (zh) 2021-03-09 2024-04-26 基因泰克公司 用于脑癌治疗的贝伐拉非尼
US20240366609A1 (en) 2021-04-06 2024-11-07 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019033B2 (en) * 1997-07-01 2006-03-28 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
WO2007044515A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
CN101605540A (zh) * 2006-12-14 2009-12-16 埃克塞利希斯股份有限公司 使用mek抑制剂的方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
AU685933B2 (en) 1994-04-01 1998-01-29 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU5610398A (en) 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
BR9810385A (pt) 1997-07-01 2000-09-05 Warner Lambert Co Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
AU2180500A (en) 1998-12-15 2000-07-03 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
AP2001002175A0 (en) 1998-12-22 2001-06-21 Warner Lambert Co Combination chemotherapy.
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
EP1140062B1 (en) 1999-01-07 2005-04-06 Warner-Lambert Company LLC Treatment of asthma with mek inhibitors
DE69926914T2 (de) 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-heterozyklus-substituierte diarylaminen
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
ES2208364T3 (es) 1999-07-16 2004-06-16 Warner-Lambert Company Llc Procedimiento para tratar dolor cronico usando inhibidores de mek.
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
KR20020012315A (ko) 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
HUP0202381A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
SK2072003A3 (en) * 2000-08-25 2004-01-08 Warner Lambert Co Process for making N-aryl-anthranilic acids and their derivatives
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
CA2460118A1 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
CA2473545A1 (en) 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US7314873B2 (en) 2002-06-11 2008-01-01 Merck & Co., Inc. (Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US7521447B2 (en) 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
CA2528602A1 (en) 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
TW200520745A (en) 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
WO2005058887A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivates
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
ZA200703912B (en) 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
US9765032B2 (en) 2014-02-07 2017-09-19 Sumitomo Chemical Company, Limited Method for producing (R)-1,1,3-trimethyl-4-aminoindane
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019033B2 (en) * 1997-07-01 2006-03-28 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
WO2007044515A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
CN101605540A (zh) * 2006-12-14 2009-12-16 埃克塞利希斯股份有限公司 使用mek抑制剂的方法

Also Published As

Publication number Publication date
MX372708B (es) 2020-05-29
US9771347B2 (en) 2017-09-26
MA38085A1 (fr) 2018-08-31
SG11201502795VA (en) 2015-05-28
HK1213567A1 (zh) 2016-07-08
HK1213878A1 (en) 2016-07-15
AU2013328929B2 (en) 2018-01-04
PE20191818A1 (es) 2019-12-27
SA515360271B1 (ar) 2016-05-19
AU2013328929A1 (en) 2015-04-30
PE20151494A1 (es) 2015-11-06
IN2015DN03928A (2) 2015-10-02
CR20200237A (es) 2020-07-26
US20170349569A1 (en) 2017-12-07
CA2889466A1 (en) 2014-04-17
BR112015008113B1 (pt) 2022-05-24
JP6300042B2 (ja) 2018-03-28
PL2909188T3 (pl) 2018-08-31
SI2909188T1 (en) 2018-07-31
HRP20180670T1 (hr) 2018-07-13
CN104837826A (zh) 2015-08-12
MY186549A (en) 2021-07-26
US10793541B2 (en) 2020-10-06
US20200392104A1 (en) 2020-12-17
MX2020005533A (es) 2020-10-12
PH12015500785A1 (en) 2015-06-15
CA2889466C (en) 2021-09-14
BR112015008113A2 (pt) 2017-07-04
WO2014059422A1 (en) 2014-04-17
EP2909188B1 (en) 2018-03-07
NZ706723A (en) 2018-07-27
US20150210668A1 (en) 2015-07-30
EA201590700A1 (ru) 2015-09-30
EA030613B1 (ru) 2018-08-31
UA115455C2 (uk) 2017-11-10
JP2018052973A (ja) 2018-04-05
PE20200387A1 (es) 2020-02-24
IL238116B (en) 2018-06-28
ES2671502T3 (es) 2018-06-06
US10239858B2 (en) 2019-03-26
CL2015000926A1 (es) 2015-08-28
EP2909188A1 (en) 2015-08-26
KR102204520B1 (ko) 2021-01-20
MX2015004660A (es) 2015-08-07
CN104837826B (zh) 2018-07-27
GEP201706690B (en) 2017-06-26
JP2015533175A (ja) 2015-11-19
CR20150245A (es) 2015-11-19
ZA201502349B (en) 2019-12-18
KR20150067339A (ko) 2015-06-17
TR201807861T4 (tr) 2018-06-21
PH12015500785B1 (en) 2015-06-15
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
CN108948043A (zh) 2018-12-07
US11414396B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
CN108948043B (zh) 制备用于治疗癌症的化合物的新型方法
RS64654B1 (sr) Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom
UA125595C2 (uk) Проміжні сполуки, корисні для синтезу селективного інгібітора щодо протеїнкінази, і способи їх отримання
AU2024252230A1 (en) Synthesis of ras inhibitors
JP7729870B2 (ja) Ｓｈｐ２の活性を阻害するための化合物及び組成物の製造
CA3216857A1 (en) Process for preparing btk inhibitors
HK1213878B (en) Novel process for making compounds for use in the treatment of cancer
CA2660348C (en) A novel process for preparing 3-amino-5-fluoro-4-dialkoxypentanoic acid ester
WO2024213877A1 (en) Process
WO2010008727A1 (en) Asymmetric synthesis of allyl or allene oxindoles
JP2008505860A (ja) ２，３−ジアミノプロピオン酸誘導体のエナンチオマー体の製造方法。

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant